4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been given an average rating of “Moderate Buy” by the eleven analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $38.56.
A number of research firms have commented on FDMT. Leerink Partners cut their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Royal Bank of Canada cut their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Chardan Capital reissued a “buy” rating and set a $39.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Finally, Morgan Stanley cut their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research report on Monday, January 13th.
Read Our Latest Analysis on 4D Molecular Therapeutics
Institutional Trading of 4D Molecular Therapeutics
4D Molecular Therapeutics Stock Performance
NASDAQ FDMT opened at $4.65 on Friday. The company has a market capitalization of $214.97 million, a price-to-earnings ratio of -1.63 and a beta of 2.81. The company’s 50-day simple moving average is $6.16 and its two-hundred day simple moving average is $10.51. 4D Molecular Therapeutics has a one year low of $4.43 and a one year high of $36.25.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
- Five stocks we like better than 4D Molecular Therapeutics
- Investing in Travel Stocks Benefits
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How to Capture the Benefits of Dividend Increases
- What Does the Future Hold for Eli Lilly?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.